Best Practice & Research Clinical Rheumatology
Volume 20, Issue 4 , Pages 809-826 , August 2006

Skin disorders with arthritis

  • Victoria P. Werth, MD (Professor)

      Affiliations

    • Corresponding Author InformationCorresponding author. Address: Hospital of the University of Pennsylvania, 2 Rhoads Pavilion, 36th and Spruce Sts, Philadelphia, PA 19104, USA. Tel.: +1 215 823 4208; Fax: +1 215 823 5171.

References 

  1. NP Foundation . About psoriasis web page. Available at: http://psoriasis.orgLast accessed July 2005
  2. Gladman DD. Psoriatic arthritis. Dermatologic Therapy. 2004;17:350–363
  3. Biondi Oriente C, Scarpa R, Pucino A, Oriente P. Psoriasis and psoriatic arthritis. Dermatological and rheumatological co-operative clinical report. Acta Dermato-Venereologica. Supplementum (Stockh). 1989;146:69–71
  4. Rajendran CP, Ledge SG, Rani KP, Madhavan R. Psoriatic arthritis. The Journal of the Association of Physicians of India. 2003;51:1065–1068
  5. Queiro R, Torre JC, Belzunegui J, et al. Clinical features and predictive factors in psoriatic arthritis-related uveitis. Seminars in Arthritis and Rheumatism. 2002;31:264–270
  6. Gladman DD, Hing EN, Schentag CT, Cook RJ. Remission in psoriatic arthritis. The Journal of Rheumatology. 2001;28:1045–1048
  7. Moll JM, Wright V. Psoriatic arthritis. Seminars in Arthritis and Rheumatism. 1973;3:55–78
  8. De Simone C, Guerriero C, Giampetruzzi AR, et al. Achilles tendinitis in psoriasis: clinical and sonographic findings. Journal of the American Academy of Dermatology. 2003;49:217–222
  9. Stevens KJ, Smith SL, Preston BJ, Deighton C. Tumoral enthesopathy in psoriasis. Rheumatology (Oxford). 2001;40:342–344
  10. Gladman DD, Antoni C, Mease P, et al. Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Annals of the Rheumatic Diseases. 2005;64(supplement 2):ii14–ii17
  11. Marsal S, Armadans-Gil L, Martinez M, et al. Clinical, radiographic and HLA associations as markers for different patterns of psoriatic arthritis. Rheumatology (Oxford). 1999;38:332–337
  12. Ory PA, Gladman DD, Mease PJ. Psoriatic arthritis and imaging. Annals of the Rheumatic Diseases. 2005;64(supplement 2):ii55–ii57
  13. McGonagle D. Imaging the joint and enthesis: insights into pathogenesis of psoriatic arthritis. Annals of the Rheumatic Diseases. 2005;64(supplement 2):ii58–ii60
  14. Mease P, Goffe BS. Diagnosis and treatment of psoriatic arthritis. Journal of the American Academy of Dermatology. 2005;52:1–19
  15. Jones G, Crotty M, Brooks P. Interventions for psoriatic arthritis. Cochrane Database of Systematic Reviews. 2000;CD000212
  16. Abu-Shakra M, Gladman DD, Thorne JC, et al. Longterm methotrexate therapy in psoriatic arthritis: clinical and radiological outcome. The Journal of Rheumatology. 1995;22:241–245
  17. Kaltwasser JP, Nash P, Gladman D, et al. Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis: a multinational, double-blind, randomized, placebo-controlled clinical trial. Arthritis and Rheumatism. 2004;50:1939–1950
  18. Klinkhoff AV, Gertner E, Chalmers A, et al. Pilot study of etretinate in psoriatic arthritis. The Journal of Rheumatology. 1989;16:789–791
  19. Mease PJ, Gladman DD, Ritchlin CT, et al. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthritis and Rheumatism. 2005;52:3279–3289
  20. Mease PJ, Kivitz AJ, Burch FX, et al. Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis and Rheumatism. 2004;50:2264–2272
  21. Mease PJ, Antoni CE. Psoriatic arthritis treatment: biological response modifiers. Annals of the Rheumatic Diseases. 2005;64(supplement 2):ii78–ii82
  22. Odom RB, James WD, Berger TG. Andrews' Diseases of the Skin. 19th edn. Philadelphia: Saunders; 2000;
  23. Thiboutot DM, Strauss JS. Diseases of the sebaceous glands. In:  Freedberg IM,  Eisen AZ,  Wolff K,  Austen KF,  Goldsmith LA,  Katz SI editor. Fitzpatrick's Dermatology in General Medicine. 6th edn. New York: McGraw-Hill; 2003;
  24. Karvonen SL. Acne fulminans: report of clinical findings and treatment of twenty-four patients. Journal of the American Academy of Dermatology. 1993;28:572–579
  25. Laasonen LS, Karvonen SL, Reunala TL. Bone disease in adolescents with acne fulminans and severe cystic acne: radiologic and scintigraphic findings. AJR. American Journal of Roentgenology. 1994;162:1161–1165
  26. Hunter LY, Hensinger RN. Destructive arthritis associated with acne fulminans: a case report. Annals of the Rheumatic Diseases. 1980;39:403–405
  27. Piazza I, Giunta G. Lytic bone lesions and polyarthritis associated with acne fulminans. The Bristish Journal of Rheumatology. 1991;30:387–389
  28. Knitzer RH, Needleman BW. Musculoskeletal syndromes associated with acne. Seminars in Arthritis and Rheumatism. 1991;20:247–255
  29. Schaeverbeke T, Lequen L, de Barbeyrac B, et al. Propionibacterium acnes isolated from synovial tissue and fluid in a patient with oligoarthritis associated with acne and pustulosis. Arthritis and Rheumatism. 1998;41:1889–1893
  30. Olafsson S, Khan MA. Musculoskeletal features of acne, hidradenitis suppurativa, and dissecting cellulitis of the scalp. Rheumatic Diseases Clinics of North America. 1992;18:215–224
  31. Erhardt E, Harangi F. Two cases of musculoskeletal syndrome associated with acne. Pediatric Dermatology. 1997;14:456–459
  32. Ellis BI, Shier CK, Leisen JJ, et al. Acne-associated spondylarthropathy: radiographic features. Radiology. 1987;162:541–545
  33. Mehrany K, Kist JM, Weenig RH, Witman PM. Acne fulminans. International Journal of Dermatology. 2005;44:132–133
  34. Seukeran DC, Cunliffe WJ. The treatment of acne fulminans: a review of 25 cases. The British Journal of Dermatology. 1999;141:307–309
  35. Elias LM, Gomez MI, Torrelo A, et al. Acne fulminans and bilateral seronegative sacroiliitis triggered by isotretinoin. The Journal of Dermatology. 1991;18:366–367
  36. Salim A, David J, Holder J. Dissecting cellulitis of the scalp with associated spondylarthropathy: case report and review. Journal of the European Academy of Dermatology and Venereology. 2003;17:689–691
  37. Rosner IA, Burg CG, Wisnieski JJ, et al. The clinical spectrum of the arthropathy associated with hidradenitis suppurativa and acne conglobata. The Journal of Rheumatology. 1993;20:684–687
  38. Bhalla R, Sequeira W. Arthritis associated with hidradenitis suppurativa. Annals of the Rheumatic Diseases. 1994;53:64–66
  39. Rosner IA, Richter DE, Huettner TL, et al. Spondyloarthropathy associated with hidradenitis suppurative and acne conglobata. Annals of Internal Medicine. 1982;97:520–525
  40. Thein M, Hogarth MB, Acland K. Seronegative arthritis associated with the follicular occlusion triad. Clinical and Experimental Dermatology. 2004;29:550–552
  41. Libow LF, Friar DA. Arthropathy associated with cystic acne, hidradenitis suppurativa, and perifolliculitis capitis abscedens et suffodiens: treatment with isotretinoin. Cutis. 1999;64:87–90
  42. Chamot AM, Benhamou CL, Kahn MF, et al. Acne-pustulosis-hyperostosis-osteitis syndrome. Results of a national survey. 85 cases. Revue du Rhumatisme et des Maladies Ostéo-articulaires. 1987;54:187–196
  43. Kahn MF, Khan MA. The SAPHO syndrome. Baillieres Clinical Rheumatology. 1994;8:333–362
  44. Hayem G, Bouchaud-Chabot A, Benali K, et al. SAPHO syndrome: a long-term follow-up study of 120 cases. Seminars in Arthritis and Rheumatism. 1999;29:159–171
  45. Van Doornum S, Barraclough D, McColl G, Wicks I. SAPHO: rare or just not recognized?. Seminars in Arthritis and Rheumatism. 2000;30:70–77
  46. Amital H, Applbaum YH, Aamar S, et al. SAPHO syndrome treated with pamidronate: an open-label study of 10 patients. Rheumatology (Oxford). 2004;43:658–661
  47. Iqbal M, Kolodney MS. Acne fulminans with synovitis-acne-pustulosis-hyperostosis-osteitis (SAPHO) syndrome treated with infliximab. Journal of the American Academy of Dermatology. 2005;52(supplement 1):S118–S120
  48. Kotilainen P, Merilahti-Palo R, Lehtonen OP, et al. Propionibacterium acnes isolated from sternal osteitis in a patient with SAPHO syndrome. The Journal of Rheumatology. 1996;23:1302–1304
  49. Delyle LG, Vittecoq O, Bourdel A, et al. Chronic destructive oligoarthritis associated with Propionibacterium acnes in a female patient with acne vulgaris: septic-reactive arthritis?. Arthritis and Rheumatism. 2000;43:2843–2847
  50. Elkayam O, Yaron M, Caspi D. Minocycline-induced autoimmune syndromes: an overview. Seminars in Arthritis and Rheumatism. 1999;28:392–397
  51. Hughes RA. Arthritis precipitated by isotretinoin treatment for acne vulgaris. The Journal of Rheumatology. 1993;20:1241–1242
  52. Camisa C. Acute arthritis during isotretinoin therapy for acne. Journal of the American Academy of Dermatology. 1986;15:1061–1062
  53. Kuenzli S, Saurat J-H. The retinoids. In:  Freedberg IM,  Eisen AZ,  Wolff K,  Austen KF,  Goldsmith LA,  Katz SI editor. Fitzpatrick's Dermatology in General Medicine. 6th edn. New York: McGraw-Hill; 2003;
  54. Sontheimer RD, Costner MI. Dermatomyositis. In:  Freedberg IM,  Eisen AZ,  Wolff K,  Austen KF,  Goldsmith LA,  Katz SI editor. Fitzpatrick's Dermatology in General Medicine. 6th edn. New York: McGraw-Hill; 2003;
  55. el-Azhary RA, Pakzad SY. Amyopathic dermatomyositis: retrospective review of 37 cases. Journal of the American Academy of Dermatology. 2002;46:560–565
  56. Caproni M, Cardinali C, Parodi A, et al. Amyopathic dermatomyositis: a review by the Italian Group of Immunodermatology. Archives of Dermatology. 2002;138:23–27
  57. Spiera R, Kagen L. Extramuscular manifestations in idiopathic inflammatory myopathies. Current Opinion in Rheumatology. 1998;10:556–561
  58. Callen JP. Dermatomyositis. Lancet. 2000;355:53–57
  59. Boulman N, Slobodin G, Rozenbaum M, Rosner I. Calcinosis in rheumatic diseases. Seminars in Arthritis and Rheumatism. 2005;34:805–812
  60. Porkodi R, Shanmuganandan K, Parthiban M, et al. Clinical spectrum of inflammatory myositis in South India – a ten year study. The Journal of the Association of Physicians of India. 2002;50:1255–1258
  61. Koh ET, Seow A, Ong B, et al. Adult onset polymyositis/dermatomyositis: clinical and laboratory features and treatment response in 75 patients. Annals of the Rheumatic Diseases. 1993;52:857–861
  62. Pachman LM, Hayford JR, Chung A, et al. Juvenile dermatomyositis at diagnosis: clinical characteristics of 79 children. The Journal of Rheumatology. 1998;25:1198–1204
  63. Tse S, Lubelsky S, Gordon M, et al. The arthritis of inflammatory childhood myositis syndromes. The Journal of Rheumatology. 2001;28:192–197
  64. Schumacher HR, Schimmer B, Gordon GV, et al. Articular manifestations of polymyositis and dermatomyositis. The American Journal of Medicine. 1979;67:287–292
  65. Wasko MC, Carlson GW, Tomaino MM, Oddis CV. Dermatomyositis with erosive arthropathy: association with the anti-PL-7 antibody. The Journal of Rheumatology. 1999;26:2693–2694
  66. Schedel J, Butz B, Volk M, et al. Nonerosive metacarpophalangeal arthritides in a patient with dermatomyositis. The Journal of Rheumatology. 2004;31:1457–1458
  67. Oddis CV, Medsger TA, Cooperstein LA. A subluxing arthropathy associated with the anti-Jo-1 antibody in polymyositis/dermatomyositis. Arthritis and Rheumatism. 1990;33:1640–1645
  68. Mok CC, Tsui EY, Chau SY. Erosive arthropathy in amyopathic dermatomyositis. Clinical and Experimental Rheumatology. 2003;21:409–410
  69. Targoff IN. Laboratory testing in the diagnosis and management of idiopathic inflammatory myopathies. Rheumatic Diseases Clinics of North America. 2002;28:859–890viii
  70. Brouwer R, Hengstman GJ, Vree Egberts W, et al. Autoantibody profiles in the sera of European patients with myositis. Annals of the Rheumatic Diseases. 2001;60:116–123
  71. Lyons R, Narain S, Nichols C, et al. Effective use of autoantibody tests in the diagnosis of systemic autoimmune disease. Annals of the New York Academy of Sciences. 2005;1050:217–228
  72. Mantegazza R, Bernasconi P, Confalonieri P, Cornelio F. Inflammatory myopathies and systemic disorders: a review of immunopathogenetic mechanisms and clinical features. Journal of Neurology. 1997;244:277–287
  73. Jaworsky C. Connective tissue diseases. In:  Elder DE,  Elenitsas R,  Johnson BL,  Murphy GF editor. Lever's Histopathology of the Skin. 9th edn. Philadelphia: Lippincott Williams and Wilkins; 2005;
  74. Sigurgeirsson B, Lindelof B, Edhag O, Allander E. Risk of cancer in patients with dermatomyositis or polymyositis. A population-based study. The New England Journal of Medicine. 1992;326:363–367
  75. Buchbinder R, Forbes A, Hall S, et al. Incidence of malignant disease in biopsy-proven inflammatory myopathy. A population-based cohort study. Annals of Internal Medicine. 2001;134:1087–1095
  76. Hill CL, Zhang Y, Sigurgeirsson B, et al. Frequency of specific cancer types in dermatomyositis and polymyositis: a population-based study. Lancet. 2001;357:96–100
  77. Dalakas MC, Hohlfeld R. Polymyositis and dermatomyositis. Lancet. 2003;362:971–982
  78. Callen JP. When and how should the patient with dermatomyositis or amyopathic dermatomyositis be assessed for possible cancer?. Archives of Dermatology. 2002;138:969–971
  79. Wallace DJ. The use of chloroquine and hydroxychloroquine for non-infectious conditions other than rheumatoid arthritis or lupus: a critical review. Lupus. 1996;5(supplement 1):S59–S64
  80. Ang GC, Werth VP. Combination antimalarials in the treatment of cutaneous dermatomyositis: a retrospective study. Archives of Dermatology. 2005;141:855–859
  81. Schnabel A, Reuter M, Biederer J, et al. Interstitial lung disease in polymyositis and dermatomyositis: clinical course and response to treatment. Seminars in Arthritis and Rheumatism. 2003;32:273–284
  82. Choy E, Hoogendijk J, Lecky B, Winer J. Immunosuppressant and immunomodulatory treatment for dermatomyositis and polymyositis. Cochrane Database of Systematic Reviews. 2005;CD003643
  83. Cohen JB. Cutaneous involvement of dermatomyositis can respond to dapsone therapy. International Journal of Dermatology. 2002;41:182–184
  84. Levine TD. Rituximab in the treatment of dermatomyositis: an open-label pilot study. Arthritis and Rheumatism. 2005;52:601–607
  85. Majithia V, Harisdangkul V. Mycophenolate mofetil (CellCept): an alternative therapy for autoimmune inflammatory myopathy. Rheumatology (Oxford). 2005;44:386–389
  86. Marie I, Hachulla E, Hatron PY, et al. Polymyositis and dermatomyositis: short term and longterm outcome, and predictive factors of prognosis. The Journal of Rheumatology. 2001;28:2230–2237
  87. Imbert-Masseau A, Hamidou M, Agard C, et al. Antisynthetase syndrome. Joint, Bone, Spine: Revue du Rhumatisme. 2003;70:161–168
  88. Sontheimer RD, Miyagawa S. Potentially fatal interstitial lung disease can occur in clinically amyopathic dermatomyositis. Journal of the American Academy of Dermatology. 2003;48:797–798
  89. Luz FB, Gaspar TAP, Kalil-Gaspar N, Ramos-e-Silva M. Multicentric reticulohistiocytosis. Journal of the European Academy of Dermatology and Venereology. 2001;15:524–531
  90. Katz RW, Anderson KF. Multicentric reticulohistiocytosis. Oral surgery, oral Medicine, Oral Pathology, Oral Radiology, and Endodontics. 1988;65:721–725
  91. Hsiung SH, Chan EF, Elenitsas R, et al. Multicentric reticulohistiocytosis presenting with clinical features of dermatomyositis. Journal of the American Academy of Dermatology. 2003;48(supplement):S11–S14
  92. Hiramanek N, Kossard S, Barnetson RS. Multicentric reticulohistiocytosis presenting with a rash and arthralgia. The Australasian Journal of Dermatology. 2002;43:136–139
  93. Yee KC, Bowker CM, Tan CY, Palmer RG. Cardiac and systemic complications in multicentric reticulohistiocytosis. Clinical and Experimental Dermatology. 1993;18:555–558
  94. Liu YH, Fang K. Multicentric reticulohistiocytosis with generalized systemic involvement. Clinical and Experimental Dermatology. 2004;29:373–376
  95. Bogle MA, Tschen JA, Sairam S, et al. Multicentric reticulohistiocytosis with pulmonary involvement. Journal of the American Academy of Dermatology. 2003;49:1125–1127
  96. Burgdorf WHC, Zelger B. The histiocytoses. In:  Elder DE,  Elenitsas R,  Johnson BL,  Murphy GF editor. Lever's Histopathology of the Skin. 9th edn. Philadelphia: Lippincott Williams and Wilkins; 2005;
  97. Sellam J, Deslandre CJ, Dubreuil F, et al. Refractory multicentric reticulohistiocytosis treated by infliximab: two cases. Clinical and Experimental Rheumatology. 2005;23:97–99
  98. Kovach BT, Calamia KT, Walsh JS, Ginsburg WW. Treatment of multicentric reticulohistiocytosis with etanercept. Archives of Dermatology. 2004;140:919–921
  99. Rapini RP. Multicentric reticulohistiocytosis. Clinics in Dermatology. 1993;11:107–111
  100. Cohen PR, Kurzrock R. Sweet's syndrome: a neutrophilic dermatosis classically associated with acute onset and fever. Clinics in Dermatology. 2000;18:265–282
  101. von den Driesch P. Sweet's syndrome (acute febrile neutrophilic dermatosis). Journal of the American Academy of Dermatology. 1994;31:535–556[quiz 557–560]
  102. Cohen PR, Kurzrock R. Sweet's syndrome revisited: a review of disease concepts. International Journal of Dermatology. 2003;42:761–778
  103. Callen JP. Neutrophilic dermatoses. Dermatologic Clinics. 2002;20:409–419
  104. Cohen PR, Holder WR, Tucker SB, et al. Sweet syndrome in patients with solid tumors. Cancer. 1993;72:2723–2731
  105. Satra K, Zalka A, Cohen PR, Grossman ME. Sweet's syndrome and pregnancy. Journal of the American Academy of Dermatology. 1994;30:297–300
  106. Walker DC, Cohen PR. Trimethoprim-sulfamethoxazole-associated acute febrile neutrophilic dermatosis: case report and review of drug-induced Sweet's syndrome. Journal of the American Academy of Dermatology. 1996;34:918–923
  107. Kemmett D, Hunter JA. Sweet's syndrome: a clinicopathologic review of twenty-nine cases. Journal of the American Academy of Dermatology. 1990;23:503–507
  108. Moreland LW, Brick JE, Kovach RE, et al. Acute febrile neutrophilic dermatosis (Sweet syndrome): a review of the literature with emphasis on musculoskeletal manifestations. Seminars in Arthritis and Rheumatism. 1988;17:143–153
  109. Gunawardena DA, Gunawardena KA, Ratnayaka RM, Vasanthanathan NS. The clinical spectrum of Sweet's syndrome (acute febrile neutrophilic dermatosis) – a report of eighteen cases. The British Journal of Dermatology. 1975;92:363–373
  110. Nolla JM, Juanola X, Valverde J, et al. Arthritis in acute febrile neutrophilic dermatosis (Sweet's syndrome). Annals of the Rheumatic Diseases. 1990;49:135
  111. Krauser RE, Schumacher HR. The arthritis of Sweet's syndrome. Arthritis and Rheumatism. 1975;18:35–41
  112. Su WP, Liu HN. Diagnostic criteria for Sweet's syndrome. Cutis. 1986;37:167–174
  113. Cohen PR, Kurzrock R. Sweet's syndrome: a review of current treatment options. American Journal of Clinical Dermatology. 2002;3:117–131
  114. Gouliaris A, Papadakis P, Kranias D, et al. Sweet's syndrome with arthritis and vasculitis. Clinical Rheumatology. 2003;22:244–247
  115. Su WP, Davis MD, Weenig RH, et al. Pyoderma gangrenosum: clinicopathologic correlation and proposed diagnostic criteria. International Journal of Dermatology. 2004;43:790–800
  116. Wolff K, Stingl G. Pyoderma gangrenosum. In:  Freedberg IM,  Eisen AZ,  Wolff K,  Austen KF,  Goldsmith LA,  Katz SI editor. Fitzpatrick's Dermatology in General Medicine. 6th edn. New York: McGraw-Hill; 2003;
  117. Powell FC, Schroeter AL, Su WP, Perry HO. Pyoderma gangrenosum: a review of 86 patients. The Quarterly Journal of Medicine. 1985;55:173–186
  118. Callen JP. Pyoderma gangrenosum. Lancet. 1998;351:581–585
  119. von den Driesch P. Pyoderma gangrenosum: a report of 44 cases with follow-up. The British Journal of Dermatology. 1997;137:1000–1005
  120. Wines N, Wines M, Ryman W. Understanding pyoderma gangrenosum: a review. Medscape General Medicine. 2001;3:6
  121. Holt PJ, Davies MG, Saunders KC, Nuki G. Pyoderma gangrenosum: clinical and laboratory findings in 15 patients with special reference to polyarthritis. Medicine (Baltimore). 1980;59:114–133
  122. Prystowsky JH, Kahn SN, Lazarus GS. Present status of pyoderma gangrenosum. Review of 21 cases. Archives of Dermatology. 1989;125:57–64
  123. Olivieri I, Costa AM, Cantini F, et al. Pyoderma gangrenosum in association with undifferentiated seronegative spondylarthropathy. Arthritis and Rheumatism. 1996;39:1062–1065
  124. Crowson AN, Mihm MC, Magro C. Pyoderma gangrenosum: a review. Journal of Cutaneous Pathology. 2003;30:97–107
  125. Reichrath J, Bens G, Bonowitz A, Tilgen W. Treatment recommendations for pyoderma gangrenosum: an evidence-based review of the literature based on more than 350 patients. Journal of the American Academy of Dermatology. 2005;53:273–283
  126. Brooklyn TN, Dunnill GS, Shetty A, et al. Infliximab for the treatment of pyoderma gangrenosum: a randomised, double-blind placebo-controlled trial. Gut. 2006;55:505–509
  127. Kontochristopoulos GJ, Stavropoulos PG, Gregoriou S, Zakopoulou N. Treatment of pyoderma gangrenosum with low-dose colchicine. Dermatology. 2004;209:233–236
  128. Lindor NM, Arsenault TM, Solomon H, et al. A new autosomal dominant disorder of pyogenic sterile arthritis, pyoderma gangrenosum, and acne: PAPA syndrome. Mayo Clinic Proceedings. 1997;72:611–615
  129. Wise CA, Gillum JD, Seidman CE, et al. Mutations in CD2BP1 disrupt binding to PTP PEST and are responsible for PAPA syndrome, an autoinflammatory disorder. Human Molecular Genetics. 2002;11:961–969
  130. Yeon HB, Lindor NM, Seidman JG, Seidman CE. Pyogenic arthritis, pyoderma gangrenosum, and acne syndrome maps to chromosome 15q. American Journal of Human Genetics. 2000;66:1443–1448
  131. Stichweh DS, Punaro M, Pascual V. Dramatic improvement of pyoderma gangrenosum with infliximab in a patient with PAPA syndrome. Pediatric Dermatology. 2005;22:262–265
  132. Dierselhuis MP, Frenkel J, Wulffraat NM, Boelens JJ. Anakinra for flares of pyogenic arthritis in PAPA syndrome. Rheumatology (Oxford). 2005;44:406–408
  133. Fiorentino DF. Cutaneous vasculitis. Journal of the American Academy of Dermatology. 2003;48:311–340
  134. Gyselbrecht L, De Keyser F, Ongenae K, et al. Etiological factors and underlying conditions in patients with leucocytoclastic vasculitis. Clinical and Experimental Rheumatology. 1996;14:665–668
  135. Crowson AN, Mihm MC, Magro CM. Cutaneous vasculitis: a review. Journal of Cutaneous Pathology. 2003;30:161–173
  136. Jessop SJ. Cutaneous leucocytoclastic vasculitis: a clinical and aetiological study. The Bristish Journal of Rheumatology. 1995;34:942–945
  137. Sais G, Vidaller A, Jucgla A, et al. Prognostic factors in leukocytoclastic vasculitis: a clinicopathologic study of 160 patients. Archives of Dermatology. 1998;134:309–315
  138. Martinez-Taboada VM, Blanco R, Garcia-Fuentes M, Rodriguez-Valverde V. Clinical features and outcome of 95 patients with hypersensitivity vasculitis. The American Journal of Medicine. 1997;102:186–191
  139. Wahl CE, Bouldin MB, Gibson LE. Erythema elevatum diutinum: clinical, histopathologic, and immunohistochemical characteristics of six patients. The American Journal of Dermatopathology. 2005;27:397–400
  140. Katz SI, Gallin JI, Hertz KC, et al. Erythema elevatum diutinum: skin and systemic manifestations, immunologic studies, and successful treatment with dapsone. Medicine (Baltimore). 1977;56:443–455
  141. Wilkinson SM, English JS, Smith NP, et al. Erythema elevatum diutinum: a clinicopathological study. Clinical and Experimental Dermatology. 1992;17:87–93
  142. Davis MD, Daoud MS, Kirby B, et al. Clinicopathologic correlation of hypocomplementemic and normocomplementemic urticarial vasculitis. Journal of the American Academy of Dermatology. 1998;38:899–905
  143. Moreland LW, Ball GV. Cutaneous polyarteritis nodosa. The American Journal of Medicine. 1990;88:426–430
  144. Chen KR. Cutaneous polyarteritis nodosa: a clinical and histopathological study of 20 cases. The Journal of Dermatology. 1989;16:429–442
  145. Sinovich V, Snow J. Protracted superficial Wegener's granulomatosis. The Australasian Journal of Dermatology. 2003;44:207–214
  146. Kihiczak D, Nychay SG, Schwartz RA, et al. Protracted superficial Wegener's granulomatosis. Journal of the American Academy of Dermatology. 1994;30:863–866

PII: S1521-6942(06)00049-0

doi: 10.1016/j.berh.2006.05.001

Best Practice & Research Clinical Rheumatology
Volume 20, Issue 4 , Pages 809-826 , August 2006

Article Tools

* Image Usage & Resolution